|
1
|
Aguirre AJ, Bardeesy N, Sinha M, Lopez L,
Tuveson DA, Horner J, Redston MS and DePinho RA: Activated Kras and
Ink4a/Arf deficiency cooperate to produce metastatic pancreatic
ductal adenocarcinoma. Genes Dev. 17:3112–3126. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Garcia M, Jemal A, Ward EM, Center MM, Hao
Y, Siegel RL and Thun MJ: Global Cancer Facts & Figures 2007.
Atlanta, GA: American Cancer Society. 2007.
|
|
3
|
Conlon KC, Klimstra DS and Brennan MF:
Long-term survival after curative resection for pancreatic ductal
adenocarcinoma. Histopathology. Ann Surg. 223:273–279. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sarkar FH, Banerjee S and Li Y: Pancreatic
cancer, pathogenesis, prevention and treatment. Toxicol Appl
Pharmacol. 224:326–336. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Berthelemy P, Bouisson M, Escourrou J,
Vaysse N, Rumeau JL and Pradayrol L: Identification of K-ras
mutations in pancreatic juice in the early diagnosis of pancreatic
cancer. Ann Intern Med. 123:188–191. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iacobuzio-Donahue CA, Ashfaq R, Maitra A,
Adsay NV, Shen-Ong GL, Berg K, Hollingsworth MA, Cameron JL, Yeo
CJ, Kern SE, et al: Highly expressed genes in pancreatic ductal
adenocarcinomas: a comprehensive characterization and comparison of
the transcription profiles obtained from three major technologies.
Cancer Res. 63:8614–8622. 2003.PubMed/NCBI
|
|
7
|
Park M, Kim M, Hwang D, Park M, Kim WK,
Kim SK, Shin J, Park ES, Kang CM, Paik YK and Kim H:
Characterization of gene expression and activated signaling
pathways in solid-pseudopapillary neoplasm of pancreas. Mod Pathol.
27:580–593. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Irizarry RA, Hobbs B, Collin F,
Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP:
Exploration, normalization and summaries of high density
oligonucleotide array probe level data. Biostatistics. 4:249–264.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gautier L, Cope L, Bolstad BM and Irizarry
RA: Affy-analysis of Affymetrix GeneChip data at the probe level.
Bioinformatics. 20:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Smyth GK: Limma: linear models for
microarray data. Bioinformatics and Computational Biology Solutions
using R and Bioconductor. Gentleman R, Carey V, Dudoit S, Irizarry
R and Huber W: (New York, Springer). Springer. 397–420. 2005.
View Article : Google Scholar
|
|
11
|
The Gene Ontology Consortium. Ashburner M,
Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP,
Dolinski K, Dwight SS, Eppig JT, et al: Gene Ontology: tool for the
unification of biology. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kanehisa M and Goto S: KEGG: Kyoto
encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang DW, Sherman BT, Tan Q, Collins JR,
Alvord WG, Roayaei J, Stephens R, Baseler MW, Lane HC and Lempicki
RA: The DAVID Gene Functional Classification Tool, a novel
biological module-centric algorithm to functionally analyze large
gene lists. Genome Biol. 8:R1832007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao M, Sun J and Zhao Z: TSGene: a web
resource for tumor suppressor genes. Nucleic Acids Res. 41(Database
issue): D970–D976. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen JS, Hung WS, Chan HH, Tsai SJ and Sun
HS: In silico identification of oncogenic potential of fyn-related
kinase in hepatocellular carcinoma. Bioinformatics. 29:420–427.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Franceschini A, Szklarczyk D, Frankild S,
Kuhn M, Simonovic M, Roth A, Lin J, Minguez P, Bork P, von Mering C
and Jensen LJ: STRING v9.1: protein-protein interaction networks,
with increased coverage and integration. Nucleic Acids Res.
41(Database issue): D808–D815. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Beisser D, Klau GW, Dandekar T, Müller T
and Dittrich MT: BioNet an R-Package for the functional analysis of
biological networks. Bioinformatics. 26:1129–1130. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sherr CJ: Cancer cell cycles. Science.
274:1672–1677. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hartwell LH and Kastan MB: Cell cycle
control and cancer. Science. 266:1821–1828. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hunter T and Pines J: Cyclins and cancer
II: cyclin D and CDK inhibitors come of age. Cell. 79:573–582.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kidokoro T, Tanikawa C, Furukawa Y, et al:
CDC20, a potential cancer therapeutic target, is negatively
regulated by p53. Oncogene. 27:1562–1571. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fung TK and Poon RY: A roller coaster ride
with the mitotic cyclins. Semin Cell Dev Biol. 16:335–342. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chang DZ, Ma Y, Ji B, Liu Y, Hwu P,
Abbruzzese JL, Logsdon C and Wang H: Increased CDC20 expression is
associated with pancreatic ductal adenocarcinoma differentiation
and progression. J Hematol Oncol. 5:152012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yamamoto Y, Matsuyama H, Chochi Y, Okuda
M, Kawauchi S, Inoue R, Furuya T, Oga A, Naito K and Sasaki K:
Overexpression of BUBR1 is associated with chromosomal instability
in bladder cancer. Cancer Genet Cytogenet. 174:42–47. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
van Deursen: JM:R b loss causes cancer by
driving mitosis mad. Cancer cell. 11:1–3. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pinto M, Vieira J, Ribeiro FR, Soares MJ,
Henrique R, Oliveira J, Jerónimo C and Teixeira MR: Overexpression
of the mitotic checkpoint genes BUB1 and BUBR1 is associated with
genomic complexity in clear cell kidney carcinomas. Cell Oncol.
30:389–395. 2008.PubMed/NCBI
|
|
27
|
Scintu M, Vitale R, Prencipe M, Gallo AP,
Bonghi L, Valori VM, Maiello E, Rinaldi M, Signori E, Rabitti C, et
al: Genomic instability and increased expression of BUB1B and
MAD2L1 genes in ductal breast carcinoma. Cancer Lett. 254:298–307.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Petitjean A, Mathe E, Kato S, Ishioka C,
Tavtigian SV, Hainaut P and Olivier M: Impact of mutant p53
functional properties on TP53 mutation patterns and tumor
phenotype, lessons from recent developments in the IARC TP53
database. Hum Mutat. 28:622–629. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hingorani SR, Wang L, Multani AS, Combs C,
Deramaudt TB, Hruban RH, Rustgi AK, Chang S and Tuveson DA:
Trp53R172H and KrasG12D cooperate to promote chromosomal
instability and widely metastatic pancreatic ductal adenocarcinoma
in mice. Cancer Cell. 7:469–483. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Suzuki T, Urano T, Miki Y, Moriya T,
Akahira J, Ishida T, Horie K, Inoue S and Sasano H: Nuclear cyclin
B1 in human breast carcinoma as a potent prognostic factor. Cancer
Sci. 98:644–651. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang A, Yoshimi N, Ino N, Tanaka T and
Mori H: Overexpression of cyclin B1 in human colorectal cancers. J
Cancer Res Clin Oncol. 123:124–127. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
El-Ghobashy AA, Shaaban AM, Herod J, et
al: Overexpression of cyclins A and B as markers of neoplastic
glandular lesions of the cervix. Gynecol Oncol. 92:628–634. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Weissmueller S, Manchado E, Saborowski M,
et al: Mutant p53 drives pancreatic cancer metastasis through
cell-autonomous PDGF receptor β signaling. Cell. 157:382–394. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yin XY, Grove L, Datta NS, Katula K, Long
MW and Prochownik EV: Inverse regulation of cyclin B1 by c-Myc and
p53 and induction of tetraploidy by cyclin B1 overexpression.
Cancer Res. 61:6487–6493. 2001.PubMed/NCBI
|
|
35
|
Zhang X, Horwitz GA, Prezant TR, et al:
Structure, expression and function of human pituitary
tumor-transforming gene (PTTG). Mol Endocrinol. 13:156–166. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pei L and Melmed S: Isolation and
characterization of a pituitary tumor-transforming gene (PTTG). Mol
Endocrinol. 11:433–441. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ying H, Furuya F, Zhao L, Araki O, West
BL, Hanover JA, Willingham MC and Cheng SY: Aberrant accumulation
of PTTG1 induced by a mutated thyroid hormone β receptor inhibits
mitotic progression. J Clin Invest. 116:2972–2984. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Genkai N, Homma J, Sano M, Tanaka R and
Yamanaka R: Increased expression of pituitary tumor-transforming
gene (PTTG)-1 is correlated with poor prognosis in glioma patients.
Oncol Rep. 15:1569–1574. 2006.PubMed/NCBI
|
|
39
|
Heaney AP, Singson R, McCabe CJ, Nelson V,
Nakashima M and Melmed S: Expression of pituitary-tumour
transforming gene in colorectal tumours. Lancet. 355:716–719. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Solbach C, Roller M, Fellbaum C, Nicoletti
M and Kaufmann M: PTTG mRNA expression in primary breast cancer, a
prognostic marker for lymph node invasion and tumor recurrence.
Breast. 13:80–81. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Puri R, Tousson A, Chen L and Kakar SS:
Molecular cloning of pituitary tumor transforming gene 1 from
ovarian tumors and its expression in tumors. Cancer Lett.
163:131–139. 2001. View Article : Google Scholar : PubMed/NCBI
|
